Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides an effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II-IIIA breast cancer.
De Giorgi U, Rosti G, Zaniboni A, Ballardini M, Minzi MR, Baioni M, Ferrari E, Zornetta L, Marangolo M. De Giorgi U, et al. Among authors: marangolo m. Bone Marrow Transplant. 2003 Aug;32(3):251-5. doi: 10.1038/sj.bmt.1704125. Bone Marrow Transplant. 2003. PMID: 12858195 Clinical Trial.
A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization.
Kopf B, De Giorgi U, Vertogen B, Monti G, Molinari A, Turci D, Dazzi C, Leoni M, Tienghi A, Cariello A, Argnani M, Frassineti L, Scarpi E, Rosti G, Marangolo M. Kopf B, et al. Among authors: marangolo m. Bone Marrow Transplant. 2006 Sep;38(6):407-12. doi: 10.1038/sj.bmt.1705465. Bone Marrow Transplant. 2006. PMID: 16951690 Clinical Trial.
Multiple cycles of PBPC-supported high-dose carboplatin and paclitaxel following mobilization with epirubicin and cisplatin are feasible but ineffective in treating patients with advanced non-small cell lung cancer.
De Giorgi U, Rosti G, Ciucci G, Kopf B, Minzi C, Argnani M, Marangolo M. De Giorgi U, et al. Among authors: marangolo m. Bone Marrow Transplant. 2007 Oct;40(8):735-9. doi: 10.1038/sj.bmt.1705793. Epub 2007 Aug 13. Bone Marrow Transplant. 2007. PMID: 17700603
Prevention and therapy of neutropenia in elderly patients.
Rosti G, Kopf B, Cariello A, Monti M, Dazzi C, Papiani G, Giovanis P, De Giorgi U, Marangolo M. Rosti G, et al. Among authors: marangolo m. Crit Rev Oncol Hematol. 2003 Jun;46(3):247-53. doi: 10.1016/s1040-8428(03)00024-6. Crit Rev Oncol Hematol. 2003. PMID: 12791424 Review.
The use of granulocyte colony-stimulating factors following peripheral blood progenitor cell rescue after high-dose chemotherapy for advanced breast cancer: a prospective study.
Dazzi C, Albertazzi L, Rosti G, Maestri A, Fiorentini G, Leoni M, Tienghi A, Turci D, Ferrante P, Vertogen B, Cariello A, Latino W, Zumaglini F, Marangolo M. Dazzi C, et al. Among authors: marangolo m. Tumori. 1997 Nov-Dec;83(6):900-3. doi: 10.1177/030089169708300605. Tumori. 1997. PMID: 9526580 Clinical Trial.
158 results